INmune Bio Inc (INMB)

https://investorshub.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/98808296/inmune-bio-inc-achieves-mhra-approval-of-pip-for

https://investorshub.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/trades

It failed in the first trial https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171636087 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174142836

It failed in the second trial https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175902173 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176527055

They now talk about a phase two expansion trial in solid tumours with residual disease.

Wen $10? 
GL here

2.35

From the wording of the press release, it seems there was (at least some) activity, but not enough to translate into any CRs or PRs https://finance.yahoo.com/news/inmune-bio-care-pc-trial-120000411.html

The trial missed its primary endpoint. The trial also missed its secondary endpoints. I doubt they will find a partner to advance it.

Perhaps INMB wojld have benefitted from using the FDA’s open label adaptive ph 2 cross over trial like Anavex did. We are clearly on a firm foundation of efficacy because if the ph 2a as we near approval in the EU.

On a financing note, yes I also highly appreciate Dr. Missling’s clear savvy moves to minimally allow dilution to Anavex shareholders on the way to approval…..inhouse!

Management of INMB should be ashamed for securing a financing deal ahead of releasing bad news. Did the funding source know the data and shorted against the box? Smells very bad!

Every Alzheimer's trial fail makes me appreciate AVXL that much more...

Yes indeed! Fortunately it was a small stake...not much effect on the portfolio.

Looks like a terrible decision 

The low 5's after the 20% share increase priced at 6.30 provided a nice entry point...and not long to wait to see it it was a good decision.

Happens all the time.  Not a surprise.

$5's

Then they dropped an offering at $6.30. What a shit move. 

OFFERING - @ $6.30 per share.....

$13s 

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
https://ih.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/96320079/inmune-bio-inc-to-announce-top-line-results-from
GhosT

An update https://www.globenewswire.com/news-release/2025/06/02/3091859/0/en/Syncromune-Inc-Presents-Positive-Results-from-SYNC-T-Therapy-SV-102-Phase-1-Metastatic-Prostate-Cancer-Trial-at-ASCO-2025.html

https://www.globenewswire.com/news-release/2025/05/30/3091053/0/en/Syncromune-Announces-First-Patient-Dosed-in-LEGION-100-Phase-2a-Trial-of-SYNC-T-Therapy-SV-102-for-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer.html

Apples to oranges, but this is the kind of data you want to see https://syncromune.com/wp-content/uploads/2024/04/SYNC-T-AACR-Website.pdf

So no scans, waterfall or swimmer plots! Doesn't look like there is any single-agent activity https://archive.fast-edgar.com/20250304/AD29K22CLM22K282222G22Y2M9BIZ2224272/ea023314201ex99-1_inmune.htm

Drugs with no single-agent activity rarely, if ever improve outcomes in randomised and controlled trials when used alone or in combination.

ELAB Partnership

INMB under $5

INMB new 52 week low

Study Demonstrate XPro converts microglia from a demyelinating cell to a remyelinating cell.Multi-year study published has implications for many CNS diseases including Alzheimer's.

INMB 5.27 something brewing over here in some

INMB new 52 week low

INMB under $10

''The third patient for the INKmune™ AML program in UK and EU has been enrolled and subsequent to their completion of follow-up, the company will wind down the AML program to focus resources on the prostate-cancer program and other solid tumors.'' https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html

Good luck to them in solid tumours!

INMB indeed it did

Starting to move up!

Did the trial in ovarian ever start?

Don't need to convince us. We are fully invested and believers in both the INKmune NK cell therapy for certain cancers as well as XPro for AD and possibly others neuro inflammation sensitive diseases, including Parkinson’s.

Two robust programs and each have multi-billion value potential based on TAM

Exciting times.

GLTA longs

Sure, it is early days in patients, but the data has yet to be https://ashpublications.org/blood/article/140/Supplement%201/4590/492304/In-Vivo-Generation-of-Memory-like-NK-Cells-for-the

Keep in mind that the ORR (focusing on R/R AML) is ~30-35% across multiple trials using adoptive transfer of non-engineered NK cells.

blocked

INMB chart....finally a reversal?

INMB Chart

XPro news also impressive. Data very.

“The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio

INKmune news was impressive. Albeit one patient dosed additional eight (8) in line. No toxicity. Ovarian cancer on deck.

https://finance.yahoo.com/news/inmune-bio-inc-announces-biomarker-200000970.html

Almost, $13 to $10 is a downward slope. but maybe over time things will be reversed??

Booooooom? More like, BurP! LOL. Still researching INMB

New run began today. Deeper dive Alzheimer’s drug they’re developing is phenomenal. Early studies some patients seeing reversed effects.

Unbelievable.

$INMB just ran from $2.00 to 30.00 congrats to the longs. what a beast of a stock.



*INmune Bio shares are trading higher after the company announced results for its Phase 1B study of XPro1595. The results show a decrease in biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid and MRI.



$PDSB CD8+ (killer) T-cells. T cell platform is next.


$INMB

I need a bigger rake to scoop up all this cash trade....

Still crickets here....

Good enough for Harry Reid it's good enough for me. I'm in for the 50's

They are speaking with Roth Capital right now

Shorts bring this to 8 I wanna buy

INMB CHART >>>> going in position before test $25 next days again. after $25 blue skies... $13-$15 range a gift imho think will run big next days

Wow that public offering is peanuts ...Kaboom here tomorrow